|
Compound class:
Antibody
Comment: Rolistobart is an anti-leukocyte immunoglobulin like receptor B4 (LILRB4) monoclonal antibody. It is proposed as an immunotherapeutic that is designed to disrupt the immunosuppressive LILRB4 checkpoint, and to restore anti-tumour immunity. Peptide sequences for the heavy and light chains of the antibody are claimed in Merck patent US11111297B2, with the humanized antibody referred to as mAb 46 (52B8 VH1 M64V/VL5 N34Q IgG4 S228P/Kappa) [1]. Rolistobart is likely intended as the INN for MK-0482.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use ![]() |
| MK-0482 was progressed as an immuno-oncology agent. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | Phase 1/Phase 2 Interventional | Merck Sharp & Dohme LLC | ||
| NCT04165083 | KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) | Phase 2 Interventional | Merck Sharp & Dohme LLC | ||
| NCT06413095 | PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS | Early Phase 1 Interventional | Presage Biosciences | ||